A carregar...
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. In this phase 3 randomized, c...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6468595/ https://ncbi.nlm.nih.gov/pubmed/30875928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030366 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|